Drug development using both top-down pharmacokinetic/pharmacodynamic models as well as bottom-up mechanistic approaches for small molecules and large biologics.


Specifications

  • FIRST PLATFORM THAT RELATES PK SPECIFIC EFFECTS TO PD ENDPOINTS

  • INLINE MEASUREMENT OF INFLAMMATORY BIOMARKERS & METABOLITES AS A FUNCTION OF PK

  • ENDPOINT MOLECULAR ASSAYS

  • DELIVERY OF SINGER OR MULTIPLE DRUGS/BIOLOGICS FOR SCHEDULE AND COMBINATION INVESTIGATIONS

How it works:

Design optimal dosing and therapy regimens for maximum efficiency and minimum side effects

Case Study:

Treatment Synergism: Schedule Dependence
Host-specific PK helps to explain the disconnect between observed schedule dependent synergism in-vitro and lack thereof under in-vivo condition.
Schedule Dependent Input Profiles
*Representative data